Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Plos One|October 2, 2014
Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr miceQingran Yan, Fang Du, Xinfang Huang, et al.Frontiers in Medicine|October 25, 2021
Association of Cytomegalovirus Infection With Anti-MDA5 Antibody-Positive Dermatomyositis: A Prospective Cohort StudyLinlin Huang, Wenbo Zhu, Yan Ye, et al.Frontiers in Immunology|March 27, 2023
Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational studyQingran Yan, Mei Zhang, Fang Du, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 9, 2022
Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndromeQianqian Li, Rui Li, Hanlin Yin, et al.RMD Open|January 25, 2023
Quantitative infrapatellar fat pad signal intensity alteration as an imaging biomarker of knee osteoarthritis progressionHan Cen, Qingran Yan, Tao Meng, et al.Arthritis Research & Therapy|April 2, 2020
Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational studyYuening Kang, Qingran Yan, Qiong Fu, et al.Arthritis Research & Therapy|April 12, 2019
Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axisYan Ye, Mei Liu, Longhai Tang, et al.Rheumatology (Oxford, England)|April 6, 2022
Longitudinal association of infrapatellar fat pad signal intensity alteration with biochemical biomarkers in knee osteoarthritisHan Cen, Qingran Yan, Weiyu Han, et al.Arthritis Research & Therapy|August 18, 2023
Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expressionLichong Shen, Hanlin Yin, Li Sun, et al.Arthritis & Rheumatology (Hoboken, N.J.)|July 25, 2023
Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic SclerosisHanlin Yin, Oliver Distler, Lichong Shen, et al.Pageof 3